February 2020 - UFOVAX

U.S. Patent & Trademark Office has allowed Scripps Research patent application HIV-1 GP140 Immunogens Comprising Modified NHR1 Regions That Stabilize Pre-fusion Conformations.

February 24, 2020

Ufovax holds exclusive rights to develop and commercialize vaccine for HIV using this patented technology.